#ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)

MADRID, SPAIN (UroToday.com) - Presented by Petrylak DP,¹ Quinn DI,² Dreicer R,³ Antonarakis ES,⁴ Shore ND,⁵ Corman JM,⁶ Concepcion R,⁷ Pieczonka CM,⁸ Sheikh NA,⁹ DeVries T,⁹ Chang N,⁹ Campogan D,⁹ Vu T,⁹ and Drake CG⁴ at the European Society for Medical Oncology (ESMO) 2014 Congress - September 26 - 30, 2014 - Madrid, Spain.

¹Genitourinary Oncology Program, Yale Cancer Center, New Haven, CT, USA;
²University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA;
³Taussig Cancer Institute, Cleveland, OH, USA;
⁴Johns Hopkins University School of Medicine, Baltimore, MD, USA;
⁵Carolina Urologic Research Center, Myrtle Beach, SC, USA;
⁶Virginia Mason Medical Center, Seattle, WA, USA;
⁷Urology Associates, Nashville, TN, USA;
⁸Associated Medical Professionals of New York, Syracuse, NY, USA;
⁹Dendreon Corporation, Seattle, WA, USA